The Effects of Statin Therapy on Aneurysm Size, Growth Rate, and Matrix Metalloproteinases-9 Levels in Patients With Aortic Aneurysm: a Systematic Review and Meta-Analysis
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575821/
Aortic aneurysm enlargement over time causes rupture, which frequently results in death. The family of proteases known as matrix metalloproteinases (MMP) is assumed to be proteolytic activity involved in the...
Overall, this meta-analysis demonstrates that statin medication is considerably helpful in reducing aneurysm diameter size and aneurysmal growth rate in individuals with aortic aneurysm.
Share
Evolocumab in Paediatric Heterozygous Familial Hypercholesterolaemia: Cognitive Function During 80 Weeks of Open-Label Extension Treatment
Source : https://pubmed.ncbi.nlm.nih.gov/37855448/
In paediatric patients with FH, 80 weeks of open-label evolocumab treatment had no negative impact on cognitive function.
Because cholesterol is important for development and adequate function of the brain, there is a concern that lowering cholesterol in children may affect mental ability. In this study, researchers tested whether treating children with evolocumab for 80 weeks affected mental ability in performing several tasks.
Share
PCSK9 Inhibition Ameliorates Experimental Autoimmune Myocarditis by Reducing TH17 Cell Differentiation Through LDLR/STAT-3/ROR-γT Pathway
Source : https://www.sciencedirect.com/science/article/abs/pii/S1567576923012870?via=ihub
Proprotein convertase subtilisin kexin type 9 (PCSK9) was characterized as a protein regulating circulating cholesterol metabolism; however, recent st...
PCSK9 inhibition ameliorated the severity of EAM mice by reducing Th17 cell differentiation. PCSK9 is a promising target for treating myocarditis.
Share
Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia Across Five Countries: Analysis From the ZERBINI Study
Source : https://link.springer.com/article/10.1007/s40119-023-00334-5
Introduction This study characterizes patients receiving evolocumab in clinical practice and assesses treatment effectiveness, safety and persistence outcomes across five countries. Methods This retrospective and prospective observational study enrolled patients...
These findings provide real-world evidence that evolocumab use is in accordance with its international guideline-recommended place in dyslipidemia therapy, as well as confirmation of its effectiveness and safety in a heterogeneous population. Evolocumab can address a healthcare gap in the management of dyslipidemia by increasing the...
Share
PCSK9 Inhibitors Suppress Oxidative Stress and Inflammation in Atherosclerotic Development by Promoting Macrophage Autophagy
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492065/
Objectives: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a novel class of cholesterol-lowering drugs, can reduce atherosclerosis independent of systemic lipid changes. However, the mechanism by which PCSK9 inhibition protects...
This study reveals a novel protective mechanism by which PCSK9 inhibition enhances autophagy and thereby reduces oxidative stress and inflammation in atherosclerosis.
Share